Literature DB >> 27658218

Cognitive-behavior therapy singly and combined with medication for persistent insomnia: Impact on psychological and daytime functioning.

Charles M Morin1, Simon Beaulieu-Bonneau2, Lynda Bélanger3, Hans Ivers4, Montserrat Sánchez Ortuño5, Annie Vallières2, Josée Savard3, Bernard Guay6, Chantal Mérette2.   

Abstract

While impairment of daytime functioning due to poor sleep is often the main determinant for seeking treatment, few studies have examined the clinical impact of insomnia therapies on daytime outcomes. The main objective of this study was to evaluate the impact of cognitive-behavior therapy (CBT), alone and combined with medication, on various indices of daytime and psychological functioning. Participants were 160 individuals with chronic insomnia who received CBT alone or CBT plus medication (zolpidem) for an initial six-week therapy, followed by an extended six-month therapy. Participants treated with CBT initially received maintenance CBT or no additional treatment and those treated with combined therapy initially continued with CBT plus intermittent medication (prn) or CBT without medication (taper). Measures of anxiety and depressive symptoms, fatigue, quality of life, and perceived impact of sleep difficulties on various indices of daytime functioning were completed at baseline, after each treatment stage, and at six-month follow-up. Following acute treatment, significant improvements of fatigue, quality of life (mental component), anxiety, and depression were obtained in the CBT alone condition but not in the combined CBT plus medication condition. Following extended treatment, further improvements were noted for the subgroup receiving extended CBT relative to that with no additional treatment, and for the subgroup receiving CBT and intermittent medication relative to that with CBT but no medication. Improvements were well maintained at the 6-month follow-up. These findings indicate that insomnia-specific therapy is effective at improving daytime and psychological functioning in the short term, and that maintenance therapy produces an added value to optimize long-term outcomes. TRIAL REGISTRATION: www.clinicaltrials.gov (#NCT 00042146). Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CBT; Daytime functioning; Insomnia; Medication; Treatment

Mesh:

Substances:

Year:  2016        PMID: 27658218      PMCID: PMC5127752          DOI: 10.1016/j.brat.2016.09.002

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  32 in total

1.  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

Authors:  C H. Bastien; A Vallières; C M. Morin
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

2.  A placebo-controlled test of cognitive-behavioral therapy for comorbid insomnia in older adults.

Authors:  Bruce Rybarczyk; Edward Stepanski; Louis Fogg; Martita Lopez; Paulette Barry; Andrew Davis
Journal:  J Consult Clin Psychol       Date:  2005-12

3.  Validation of the Insomnia Severity Index in primary care.

Authors:  Christine Gagnon; Lynda Bélanger; Hans Ivers; Charles M Morin
Journal:  J Am Board Fam Med       Date:  2013 Nov-Dec       Impact factor: 2.657

Review 4.  Recommendations for a standard research assessment of insomnia.

Authors:  Daniel J Buysse; Sonia Ancoli-Israel; Jack D Edinger; Kenneth L Lichstein; Charles M Morin
Journal:  Sleep       Date:  2006-09       Impact factor: 5.849

5.  The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response.

Authors:  Charles M Morin; Geneviève Belleville; Lynda Bélanger; Hans Ivers
Journal:  Sleep       Date:  2011-05-01       Impact factor: 5.849

6.  Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer.

Authors:  Catherine Quesnel; Josée Savard; Sébastien Simard; Hans Ivers; Charles M Morin
Journal:  J Consult Clin Psychol       Date:  2003-02

7.  Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison.

Authors:  Gregg D Jacobs; Edward F Pace-Schott; Robert Stickgold; Michael W Otto
Journal:  Arch Intern Med       Date:  2004-09-27

Review 8.  Treating the health, quality of life, and functional impairments in insomnia.

Authors:  Andrew D Krystal
Journal:  J Clin Sleep Med       Date:  2007-02-15       Impact factor: 4.062

Review 9.  A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice.

Authors:  Andrew D Krystal
Journal:  Sleep Med Rev       Date:  2009-01-18       Impact factor: 11.609

10.  Speed and trajectory of changes of insomnia symptoms during acute treatment with cognitive-behavioral therapy, singly and combined with medication.

Authors:  Charles M Morin; Simon Beaulieu-Bonneau; Hans Ivers; Annie Vallières; Bernard Guay; Josée Savard; Chantal Mérette
Journal:  Sleep Med       Date:  2014-03-31       Impact factor: 3.492

View more
  2 in total

Review 1.  Sleep Abnormalities in Multiple Sclerosis.

Authors:  Giorgos K Sakkas; Christoforos D Giannaki; Christina Karatzaferi; Mauro Manconi
Journal:  Curr Treat Options Neurol       Date:  2019-01-31       Impact factor: 3.598

2.  Effect of Digital Cognitive Behavioral Therapy for Insomnia on Health, Psychological Well-being, and Sleep-Related Quality of Life: A Randomized Clinical Trial.

Authors:  Colin A Espie; Richard Emsley; Simon D Kyle; Christopher Gordon; Christopher L Drake; A Niroshan Siriwardena; John Cape; Jason C Ong; Bryony Sheaves; Russell Foster; Daniel Freeman; Joan Costa-Font; Antonia Marsden; Annemarie I Luik
Journal:  JAMA Psychiatry       Date:  2019-01-01       Impact factor: 21.596

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.